Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated Jun 14, 2024, titled "Press Release Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial Demonstrates Durability of Pain Relief After a Single Injection of MM-II in Patients with Painful Knee Osteoarthritis (OA)".